msDNA-HP-hFVIII

N/A

Report date: 2025/01/26 15:42:52

Base Information

Drug NamemsDNA-HP-hFVIII
Drug Alias Namenon-viral gene therapy (Mediphage Bioceuticals/Seattle Children's Research Institute/University of Waterloo/University of Washington)hFVIII gene therapy (Mediphage Bioceuticals/Seattle Children's Research Institute/University of Waterloo/University of Washington)
ClassificationBiologics
Mechanisms of ActionCoagulation factor VIII stimulants
TargetsCoagulation factor VIII
Therapy Area/IndicationsHemophilia A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMediphage Bioceuticals
China Registration ClassN/A

Develop Information

Active CompaniesMediphage BioceuticalsSeattle Children'S Research InstituteUniversity Of Washington +[4] 
Inactive CompaniesN/A
Active IndicationsHemophilia A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A